Clinical Management of Thymoma Patients

Erin M. Casey, Patrick J. Kiel, Patrick Loehrer

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Thymoma and thymic carcinomas are rare epithelial tumors that arise from the thymus gland. Current management depends on staging, with surgery being the mainstay of therapy for stages I and II disease. Combined modality therapy, including radiation and chemotherapy, is recommended for patients who have invasive and metastatic disease. Relapse has been documented decades after initial therapy with options for treating recurrent advanced stage disease. Prospective studies have been limited, and current studies aim to evaluate novel treatment options.

Original languageEnglish
Pages (from-to)457-473
Number of pages17
JournalHematology/Oncology Clinics of North America
Volume22
Issue number3
DOIs
StatePublished - Jun 2008

Fingerprint

Thymoma
Combined Modality Therapy
Thymus Gland
Therapeutics
Prospective Studies
Radiation
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Clinical Management of Thymoma Patients. / Casey, Erin M.; Kiel, Patrick J.; Loehrer, Patrick.

In: Hematology/Oncology Clinics of North America, Vol. 22, No. 3, 06.2008, p. 457-473.

Research output: Contribution to journalArticle

Casey, Erin M. ; Kiel, Patrick J. ; Loehrer, Patrick. / Clinical Management of Thymoma Patients. In: Hematology/Oncology Clinics of North America. 2008 ; Vol. 22, No. 3. pp. 457-473.
@article{7121d745d1374a799972aca141eb7f56,
title = "Clinical Management of Thymoma Patients",
abstract = "Thymoma and thymic carcinomas are rare epithelial tumors that arise from the thymus gland. Current management depends on staging, with surgery being the mainstay of therapy for stages I and II disease. Combined modality therapy, including radiation and chemotherapy, is recommended for patients who have invasive and metastatic disease. Relapse has been documented decades after initial therapy with options for treating recurrent advanced stage disease. Prospective studies have been limited, and current studies aim to evaluate novel treatment options.",
author = "Casey, {Erin M.} and Kiel, {Patrick J.} and Patrick Loehrer",
year = "2008",
month = "6",
doi = "10.1016/j.hoc.2008.03.010",
language = "English",
volume = "22",
pages = "457--473",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Clinical Management of Thymoma Patients

AU - Casey, Erin M.

AU - Kiel, Patrick J.

AU - Loehrer, Patrick

PY - 2008/6

Y1 - 2008/6

N2 - Thymoma and thymic carcinomas are rare epithelial tumors that arise from the thymus gland. Current management depends on staging, with surgery being the mainstay of therapy for stages I and II disease. Combined modality therapy, including radiation and chemotherapy, is recommended for patients who have invasive and metastatic disease. Relapse has been documented decades after initial therapy with options for treating recurrent advanced stage disease. Prospective studies have been limited, and current studies aim to evaluate novel treatment options.

AB - Thymoma and thymic carcinomas are rare epithelial tumors that arise from the thymus gland. Current management depends on staging, with surgery being the mainstay of therapy for stages I and II disease. Combined modality therapy, including radiation and chemotherapy, is recommended for patients who have invasive and metastatic disease. Relapse has been documented decades after initial therapy with options for treating recurrent advanced stage disease. Prospective studies have been limited, and current studies aim to evaluate novel treatment options.

UR - http://www.scopus.com/inward/record.url?scp=44249107049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44249107049&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2008.03.010

DO - 10.1016/j.hoc.2008.03.010

M3 - Article

C2 - 18514127

AN - SCOPUS:44249107049

VL - 22

SP - 457

EP - 473

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 3

ER -